13F-HR filed by Kalehua Capital Management LLC
Kalehua Capital Management LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-13 17:28:35 UTC, with 22 holding rows worth $132,396,155.
- Accession
- 0002106181-26-000010
- Filer
- CIK 2106181
- Filed
- 2026-11-13
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 22 entries on the cover page, a total value of $132,396,155 stated on the cover page (in dollars after the unit check, H1), rows summing to $132,396,155 with VALUE read as dollars as filed, 13F file number 028-26381. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| VERADERMICS INC | 922967104 | COMMON STOCK | 145,695 | $17,662,605 | dollars as filed | |
| EA SERIES TRUST | 02072L565 | ALPHA ARCH 1-3 | 148,471 | $17,577,482 | dollars as filed | |
| KORSANA BIOSCIENCES INC | 23255M303 | COMMON STOCK | 442,653 | $14,164,896 | dollars as filed | |
| X4 PHARMACEUTICALS INC | 98420X202 | COMMON STOCK | 3,722,840 | $10,796,236 | dollars as filed | |
| ACLARIS THERAPEUTICS INC COM | 00461U105 | Stock | 1,832,365 | $9,638,240 | dollars as filed | |
| SURROZEN INC | 86889P208 | COMMON STOCK | 286,092 | $9,206,441 | dollars as filed | |
| INHIBIKASE THERAPEUTICS INC | 45719W205 | COMMON STOCK | 3,821,890 | $7,853,984 | dollars as filed | |
| SEPTERNA INC COM | 81734D104 | Stock | 194,544 | $7,612,507 | dollars as filed | |
| Betterlife Pharma Inc F | 08772P202 | COM | 27,710,000 | $6,675,339 | dollars as filed | |
| Obsidian Therapeutics, Inc. | 67448A106 | Common Stock, $0.0001 par value per share | 416,649 | $5,720,591 | dollars as filed | |
| Inflarx Nv | N44821101 | COM | 2,921,095 | $5,257,971 | dollars as filed | |
| KORRO BIO INC | 500946108 | COMMON STOCK | 473,595 | $4,693,326 | dollars as filed | |
| ATTOVIA THERAPEUTICS INC | 04987L102 | COM | 200,000 | $3,428,000 | dollars as filed | |
| DAMORA THERAPEUTICS INC | G2646Y104 | COMM STK | 139,000 | $2,957,920 | dollars as filed | |
| UNIQURE NV | N90064101 | SHS | 79,407 | $1,918,473 | dollars as filed | |
| Gossamer Bio, Inc. | 38341P201 | Common Stock, $0.0001 par value per share | 139,366 | $1,651,487 | dollars as filed | |
| Milestone Pharmaceuticals Inc | 59935V107 | COM | 1,651,258 | $1,429,494 | dollars as filed | |
| LeonaBio Inc | 04746L203 | COM | 393,701 | $1,405,513 | dollars as filed | |
| ATRIUM THERAPEUTICS INC COM | 04965N104 | Stock | 112,652 | $932,759 | dollars as filed | |
| Instil Bio Inc | 45783C200 | COM NEW | 99,600 | $721,104 | dollars as filed | |
| ATYR PHARMA INC | 002120202 | COM NEW | 1,829,513 | $554,342 | dollars as filed | |
| KAZIA THERAPEUTICS LTD | 48669G303 | SPONSORED ADS | 56,013 | $537,445 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0002106181-26-000010 | this filing | 2026-11-13 |